Artivion (AORT) vs Edwards Lifesciences (EW)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Edwards Lifesciences (EW) has outperformed Artivion (AORT) over the past year, gaining 11.8% versus a loss of 46.7%. Over five years, AORT leads with a +1.2% price change compared with -23.5% for EW. Edwards Lifesciences is the larger company by market cap ($49.44 billion vs $1.05 billion), about 46.9 times the size.
On valuation, Edwards Lifesciences trades at a lower forward P/E (25.4x vs 28.9x for Artivion).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AORT | EW |
|---|---|---|
| Share price | $21.61 | $85.78 |
| Market cap | $1.05B | $49.44B |
| 1-day change | -1.05% | -0.81% |
| YTD return | -52.62% | +0.62% |
| 1-year return | -46.66% | +11.81% |
| 5-year return | +1.17% | -23.52% |
| P/E ratio (TTM) | — | 51.06 |
| Forward P/E | 28.88 | 25.40 |
| EPS (TTM) | $-0.07 | $1.68 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $6.07B |
| Revenue growth (YoY) | — | +11.55% |
| Net income (latest FY) | — | $1.07B |
| Gross margin | — | 78.01% |
| Operating margin | — | 20.84% |
| Net margin | — | 17.69% |
| 52-week high | $48.25 | $96.29 |
| 52-week low | $19.16 | $72.30 |
| Distance from 52-week high | -55.21% | -10.91% |
| Analyst consensus | none | buy |
| Avg. price target upside | +95.05% | +18.86% |
| Average volume | 639.01K | 3.82M |
| Shares outstanding | 48.76M | 576.40M |
| Employees | 1,800 | 16,000 |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Medical Devices |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Edwards Lifesciences is about 46.9 times larger than Artivion by market value ($49.44B vs $1.05B).
- EW has outperformed AORT by 58.5 percentage points over the past year.
About Artivion
AORT stock →Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide.
Healthcare · Medical Devices · 1,800 employees
About Edwards Lifesciences
EW stock →Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands.
Healthcare · Medical Devices · 16,000 employees
AORT vs EW FAQ
Which is bigger, Artivion or Edwards Lifesciences?
Edwards Lifesciences (EW) is larger, with a market capitalization of $49.44B compared with $1.05B for Artivion (AORT).
Which stock has performed better over the past year, AORT or EW?
EW returned +11.81% over the past 12 months, compared with -46.66% for AORT (price return, excluding dividends). Past performance does not predict future results.
Are Artivion and Edwards Lifesciences in the same industry?
Yes. Both are classified in the Medical Devices industry within the Healthcare sector.